New combo therapy holds promise for rare adrenal cancer
NCT ID NCT06006013
First seen Feb 22, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests whether combining two drugs, cabozantinib and pembrolizumab, can shrink or slow the growth of advanced adrenal cancer that has spread or cannot be removed by surgery. The trial enrolls 21 adults with this rare cancer, regardless of prior treatments. The goal is to see if the combination works better than either drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
Contact
Contact Email: •••••@•••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.